Agreement - September 22, 2021
Ascelia Pharma signs clinical collaboration agreement
Ascelia Pharma has signed an agreement with Taiho Oncology, a subsidiary of Taiho Pharmaceutical. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF (trifluridine and tipiracil) film-coated tablets for oral […]
Financing - March 22, 2021
Ascelia Pharma carries out a directed new share issue
The Issue will provide the company with SEK 200 million before transaction costs. Ascelia Pharma intends to use the net proceeds from the Issue for (i) financing the Phase II study for the oral chemotherapy drug candidate Oncoral, (ii) accelerating activities towards the commercialization of the diagnostic drug Mangoral, currently in an ongoing Phase III […]
Clinical Trials - February 20, 2020
First patient enrolled in Ascelia’s Phase III study
Ascelia Pharma has announced that the first patient has been enrolled in the company’s global Phase III clinical study SPARKLE with Mangoral in patients with severely reduced renal function and with known or suspected liver lesions. “It is an important event for patients seeking a safe agent to detect liver lesions that this pivotal Phase […]
